CTLA4 and neoplasm: In multiple syngeneic mouse tumor models, blockade of PD-1 or its ligands promoted the antitumor activity27–29, which could be further enhanced by antibodies against other negative regulators of T-cells, such as CTLA-4 and LAG330,31.